2.Akt gene therapy for cirrhotic rats with portal hypertension.
Fei-zhou HUANG ; Gang DENG ; Xun-yang LIU ; Cheng-qun LUO
Journal of Central South University(Medical Sciences) 2008;33(1):31-37
OBJECTIVE:
To determine whether there is an impaired Akt and eNOS activation in cirrhotic livers, and to investigate the feasibility of transferring adenovirus-mediated Akt gene to the liver for portal hypertension.
METHODS:
Recombinant adenovirus Ad-myr-HA-Akt and Ad-EGFP were produced by homologoas recombination in 293 cells . The Methods of compound factor, carbon tetrachloride (CCl4), corn flour, and cholesterol plus alcohol were used to construct the hepatic cirrhosis rat models. Ten normal rats were served as a normal control group, and 40 cirrhotic rats were divided into 4 groups randomly: an untreated group, an Ad-myr-HA-Akt treated group, an Ad-EGFP group, and a saline group. Ad-myr-HA-Akt, Ad-EGFP, and saline were transduced into the Ad-myr-HA-Akt treated group, Ad-EGFP group, and saline group via the tail vein respectively. Portal vein pressure, mean arterial pressure, and heart rate were measured in all rats. Protein abundance and phosphorylation status of Akt and eNOS were examined by Western blot. Spectrophotometry was used to measure the NO level. Frozen sections of the liver, heart, lung, kidney, brain, spleen, and testis were made to examine the expression of enhanced green fluorescent protein (EGFP) by fluorescence microscopy on Day 3 in the Ad-EGFP group.
RESULTS:
The concentration of recombinant adenovirus Ad-myr-HA-Akt after the purification was 5.5 x 10(11)vp/mL and that of Ad-EGFP was 6.0 x 10(11)vp/mL. Akt and eNOS phosphorylations in the liver of cirrhotic rats were obviously impaired. Adenoviral delivery of myr-Akt restored eNOS phosphorylation, increased the NO level and decreased the portal pressure after 3 days of adenoviral infection. In contrast, the livers infected with Ad-EGFP and saline were not changed. The EGFP expression was mainly found under the fluorescence microscopy on the frozen section of liver. Very little fluorescence was detected in the lung and kidney; and there was no detectable EGFP in other organs.
CONCLUSION
There is an impaired Akt and eNOS activation in the cirrhotic livers; myr-Akt gene therapy can restore the Akt activation and NO production in the cirrhotic liver, suggesting that this therapy may be helpful in treating portal hypertension.
Adenoviridae
;
genetics
;
metabolism
;
Animals
;
Carbon Tetrachloride
;
Carbon Tetrachloride Poisoning
;
Genetic Therapy
;
Hypertension, Portal
;
etiology
;
therapy
;
Liver Cirrhosis, Experimental
;
complications
;
metabolism
;
therapy
;
Male
;
Nitric Oxide Synthase Type III
;
metabolism
;
Proto-Oncogene Proteins c-akt
;
genetics
;
Random Allocation
;
Rats
;
Rats, Sprague-Dawley
3.An Experimental Model of Hepatic Fibrosis Induced by Alcohol and CCl4: Can the Lipopolysaccharide Prevent Liver Injury Induced by Alcohol and CCl4?.
Hee Bok CHAE ; Lee Chan JANG ; Seon Mee PARK ; Bo Ra SON ; Rohyun SUNG ; Jae Woon CHOI
The Korean Journal of Hepatology 2002;8(2):173-178
BACKGROUND/AIMS: It is well known that alcohol enhances the toxicity of CCl4. We tried to establish an alcoholic liver cirrhosis model by administration of alcohol and CCl4 to rats. We also wanted to know the hepatoprotective effect of low doses of lipopolysaccharide(LPS) in this animal model. METHODS: Of 20 female adult rats, 8 were ingested with alcohol ad libitum(group 1) Another 6 were ingested with 10% alcohol and 50% 1mL/kg CCl4 intragastrically by Sonde twice a week(group 2) The remaining 6 were ingested with 10% alcohol, CCl4, and 0.1mg/kg LPS intraperitoneally twice a week(group 3) The fibrosis was evaluated semiquantitatively on a scale of 0(none) to 3(cirrhosis). RESULTS: 1) After 10 weks, septal fibrosis or cirrhosis was produced in 9 out of 12 rats in groups 2 and 3 but there was no fibrotic change in group 1. 2) There was no significant difference in pathological grading between groups 2 and 3. CONCLUSIONS: Hepatic fibrosis or cirrhosis can be sufficiently induced by alcohol and repetitive CCl4 ingestion for 10 weeks. We can not prove the hepatoprotective effect of low dose LPS by semiquantitative evaluation of pathological grading.
Animals
;
Carbon Tetrachloride Poisoning/*complications
;
English Abstract
;
Ethanol/*toxicity
;
Female
;
Lipopolysaccharides/*administration & dosage
;
Liver/pathology
;
Liver Cirrhosis, Alcoholic/pathology/*prevention & control
;
Rats
;
Rats, Sprague-Dawley
4.Expression of type I inositol 1,4,5-triphosphate receptor on rat glomerular and afferent arterioles in a model of liver cirrhosis.
Jing-yan WANG ; Hong-yan LIU ; Pei LIU
Chinese Journal of Hepatology 2004;12(10):609-611
OBJECTIVETo study the expression of type I inositol 1,4,5-triphosphate receptor in rat glomerular and afferent arterioles in a model of liver cirrhosis and study the role of cross-membrane message transduction in the pathogenesis of hepatorenal syndrome.
METHODSIn a rat model of carbontetrachloride liver cirrhosis, the expression of type I inositol 1,4,5-triphosphate receptor (IP3R) on glomerular and afferent arterioles was measured by immunohistochemical method.
RESULTSIn the experimental group, 30 rats were used to make a model of liver cirrhosis. 11 rats survived during the experiment. The expression of type I IP3R on glomerular and afferent arterioles was 4.97+/-1.34 and 4.09+/-1.14 in the liver cirrhosis group, and it was 2.43+/-1.67 and 1.83+/-1.32 in the normal control rats. The differences between these two groups are statistically significant (t = 2.28, P = 0.0458).
CONCLUSIONExpression of type I IP3 receptor on rat glomerular and afferent arterioles in a model of liver cirrhosis indicated that the mechanism of cross-membrane message transduction plays a very important role in the pathogenesis of hepatorenal syndrome.
Animals ; Arterioles ; metabolism ; Calcium Channels ; biosynthesis ; genetics ; Carbon Tetrachloride ; Carbon Tetrachloride Poisoning ; Inositol 1,4,5-Trisphosphate Receptors ; Kidney ; metabolism ; Kidney Glomerulus ; blood supply ; metabolism ; Liver Cirrhosis, Experimental ; chemically induced ; complications ; metabolism ; Male ; Random Allocation ; Rats ; Rats, Wistar ; Receptors, Cytoplasmic and Nuclear ; biosynthesis ; genetics ; Renal Artery ; metabolism
5.Relationship of Propranolol Pharmacokinetic Parameters with Portosystemic Shunt in CCl4-induced cirrhotic Rats.
Dong Hee KOH ; Geun Tae PARK ; Jung Mi KIM ; Yeong Seop YUN ; Sung Hee LEE ; Dong Uk KIM ; Jin Bae KIM ; Yun Yung CHOI ; Ju Seop KANG ; Ho Soon CHOI ; Joon Soo HAHM ; Min Ho LEE
The Korean Journal of Hepatology 2002;8(3):277-287
BACKGROUND: This study was designed to determine the relationship of propranolol pharmacokinetic parameters with portosystemic shunt in CCl4-induced cirrhotic rats. METHODS: Cirrhotic rats(n=6) were induced by intramuscular injection of CCl4 in olive oil(two time per weeks) for 12 weeks. Controls (n=6) were injected intramuscularly with the same dose of olive oil for 12 weeks. We evaluated the amount of portosystemic shunt by thallium-201 per rectal scintigraphy. After intravenous bolus injection of propranolol (2mg/kg) to rats, the serum propranolol concentrations were analyzed by a HPLC-fluorimetric detector system. Pharmacokinetic parameters such as C0, AUC, t(1/2(beta)), and CLp were determined in each group. Then, a small amount of heptic tissue was obtained and subjected to determination of the hepatic collagen content by quantitating 4-hydroxyproline and were inspected by microscope after hematoxylin and eosin stain. RESULTS: In liver biopsy, liver fibrosis progressed in CCl4-induced cirrhotic rats. The serum concentrations of propranolol were significantly (p < 0.01) elevated in CCl4-induced cirrhotic rats. Mean amount of 4-hydroxyproline, mean H/L ratio, and mean AUC in CCl4-induced cirrhotic rats was significantly (p < 0.01) higher than that in control rats. There was a relationship between AUC, H/L ratio, and amount of 4-hydroxyproline. CONCLUSION: H/L ratio may help in the selection of drug dosage (especially blood flow dependent drug) in pre-clinical studies for chronic liver disease during the drug development process.
Animals
;
Carbon Tetrachloride Poisoning/*complications
;
Chromatography, High Pressure Liquid
;
English Abstract
;
Liver Cirrhosis, Experimental/*metabolism/physiopathology
;
Portal System/physiopathology
;
Propranolol/*pharmacokinetics
;
Rats
;
Rats, Sprague-Dawley
;
Thallium Radioisotopes/diagnostic use